Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants.
The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.